期刊论文详细信息
PeerJ
Sarcopenia in male patients with head and neck cancer receiving chemoradiotherapy: a longitudinal pilot study
article
Namrata S. Chauhan1  Stephen Rajan Samuel1  Niranjan Meenar1  PU Prakash Saxena2  Justin W.L. Keogh1 
[1] Department of Physiotherapy, Kasturba Medical College;Department of Radiation Oncology, Kasturba Medical College;Faculty of Health Sciences and Medicine, Bond University;Human Potential Centre, AUT University;Cluster for Health Improvement, Faculty of Science, Health, Education and Engineering, University of the Sunshine Coast
关键词: Cancer;    Chemo-radiation therapy;    Deconditioning;    Muscle strength;    Physical performance;    SARC-F;    Skeletal muscle mass;    Resistance training;   
DOI  :  10.7717/peerj.8617
学科分类:社会科学、人文和艺术(综合)
来源: Inra
PDF
【 摘 要 】

Introduction Muscle wasting conditions such as sarcopenia may be highly prevalent in advanced head and neck cancer (HNC) patients (16–71%), with these prevalence rates substantially greater in those who have received chemo-radiotherapy (CRT). According to the updated European Working Group on Sarcopenia in Older People consensus statement, sarcopenia is defined as the age-related loss of muscle strength, muscle mass and physical performance. The high prevalence of sarcopenia in HNC patients is concerning as it has been associated with substantially increased risk of CRT toxicity, respiratory complications and early mortality. With the high prevalence of HNC and sarcopenia in India and the strong link between sarcopenia and poor HNC patient outcomes, it is important to screen for the presence of sarcopenia in Indian patients receiving CRT for HNC. Methods This longitudinal pilot study aimed to routinely monitor 19 men receiving CRT for their HNC for a variety of sarcopenic-related outcomes over three time points during their 7 weeks of CRT. Participants were required to be male, with a minimum age of 30 years, with a Stage III, IVa or IVb diagnosis of HNC and be currently undergoing a 7 weeks course of CRT in an oncology department. Outcomes included probable sarcopenic diagnosis were estimated by the SARC-F, handgrip strength, skeletal muscle mass was estimated by bioelectrical impedance and physical performance was assessed by the Timed Up and Go. Repeated measures ANOVA and Bonferroni post-hoc tests were used to identify significant differences at the three time points with a p < 0.05. Results The 19 participants in this trial at a mean age of 56.5 ± 10.2 years (range = 39–75 years), with most (n = 13, 68.4%) employed in laboring occupations. At baseline, 31.5% (n = 6) of the participants already had probable sarcopenia based on their total SARC-F score, with this increasing to 89.4% (n = 17) at the end of 7 weeks CRT. In addition, significant decreases in strength, skeletal muscle mass and Timed Up and Go performance were observed, with these declines significantly greater at 7 weeks than 3 weeks after commencing CRT. Conclusions Patients with HNC undergoing 7 weeks of CRT showed clinically significant increases in the incidence of probable sarcopenia based on their total SARC-F score as well as clinically significant declines in handgrip strength, skeletal muscle mass and Timed Up and Go performance. Due to the relationship between sarcopenia and a host of adverse events related to CRT in HNC patients, these results suggest that oncologists and their allied health teams should routinely monitor these patients during CRT and provide the relevant exercise therapy and nutritional support to those patients in need.

【 授权许可】

CC BY   

【 预 览 】
附件列表
Files Size Format View
RO202307100008750ZK.pdf 759KB PDF download
  文献评价指标  
  下载次数:5次 浏览次数:0次